Přehled o publikaci
2011
The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
BOUCHAL, Pavel; Jiří JARKOVSKÝ; Kristýna HRAZDILOVÁ; Monika DVOŘÁKOVÁ; Iva STRUHÁROVÁ et. al.Basic information
Original name
The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
Name in Czech
Nové platinové cytostatikum LA-12 indukuje retinol-vázající protein 4 in vivo
Authors
BOUCHAL, Pavel (203 Czech Republic, guarantor, belonging to the institution); Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution); Kristýna HRAZDILOVÁ (203 Czech Republic); Monika DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution); Iva STRUHÁROVÁ (203 Czech Republic, belonging to the institution); Lenka HERNYCHOVÁ (203 Czech Republic); Jiří DAMBORSKÝ (203 Czech Republic, belonging to the institution); Petr SOVA (203 Czech Republic) and Bořivoj VOJTĚŠEK (203 Czech Republic)
Edition
Proteome Science, BioMed Central, 2011, 1477-5956
Other information
Language
English
Type of outcome
Article in a journal
Field of Study
Biochemistry
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
RIV identification code
RIV/00216224:14310/11:00050153
Organization
Přírodovědecká fakulta – Repository – Repository
UT WoS
000297207100001
Keywords (in Czech)
LA-12, plasma retinol-binding protein 4; RBP4; cisplatina; adamantylamin; proteomika
Keywords in English
(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12); plasma retinol-binding protein 4; RBP4; cisplatin; adamantylamine; proteomics
Links
GAP304/10/0868, research and development project. MSM0021622413, plan (intention).
Changed: 1/9/2020 11:43, RNDr. Daniel Jakubík
Abstract
V originále
Background: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. Methods: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. Results: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. Conclusions: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin.